Willemse PH - Search Results

1

High-dose methotrexate, vincristine and cisplatin as salvage treatment for relapsed non-seminomatous germ-cell cancer.

Sleijfer S, Van der Graaf WT, Willemse PH, De Vries EG, Schraffordt Koops H, Mulder NH. Sleijfer S, et al. Among authors: willemse ph. Anticancer Res. 1995 May-Jun;15(3):1039-42. Anticancer Res. 1995. PMID: 7544087 Clinical Trial.

2

Paclitaxel and carboplatin concurrent with radiotherapy for primary cervical cancer.

de Vos FY, Bos AM, Gietema JA, Pras E, Van der Zee AG, de Vries EG, Willemse PH. de Vos FY, et al. Among authors: willemse ph. Anticancer Res. 2004 Jan-Feb;24(1):345-8. Anticancer Res. 2004. PMID: 15015619 Free article. Clinical Trial.

3

Intraperitoneal chemotherapy for ovarian cancer: a question of feasibility?

Willemse PH, de Vries EG. Willemse PH, et al. Drug Resist Updat. 2003 Aug;6(4):165-7. doi: 10.1016/s1368-7646(03)00061-x. Drug Resist Updat. 2003. PMID: 12962681 Review.

4

Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer.

Gietema JA, Sleijfer DT, Willemse PH, Schraffordt Koops H, van Ittersum E, Verschuren WM, Kromhout D, Sluiter WJ, Mulder NH, de Vries EG. Gietema JA, et al. Among authors: willemse ph. Ann Intern Med. 1992 May 1;116(9):709-15. doi: 10.7326/0003-4819-116-9-709. Ann Intern Med. 1992. PMID: 1558341

5

A phase I-II study with intraperitoneal cisplatin plus systemic etoposide in patients with minimal residual ovarian cancer.

Willemse PH, Sleijfer DT, de Vries EG, Boonstra H, Bouma J, Mulder NH. Willemse PH, et al. Eur J Cancer. 1992;28(2-3):479-81. doi: 10.1016/s0959-8049(05)80081-4. Eur J Cancer. 1992. PMID: 1591067 Clinical Trial.

6

Alternating cycles of PVB and BEP in the treatment of patients with advanced seminoma.

Gietema JA, Willemse PH, Mulder NH, Oldhoff J, de Vries EG, Sleijfer DT. Gietema JA, et al. Among authors: willemse ph. Eur J Cancer. 1991;27(11):1376-9. doi: 10.1016/0277-5379(91)90013-4. Eur J Cancer. 1991. PMID: 1720634

7

CA-125 in ovarian cancer: relation between half-life, doubling time and survival.

Willemse PH, Aalders JG, de Bruyn HW, Mulder NH, Sleijfer DT, de Vries EG. Willemse PH, et al. Eur J Cancer. 1991;27(8):993-5. doi: 10.1016/0277-5379(91)90266-g. Eur J Cancer. 1991. PMID: 1832911

8

Risks and benefits of cisplatin in ovarian cancer. A quality-adjusted survival analysis.

Willemse PH, van Lith J, Mulder NH, Aalders JG, Bouma J, de Vries EG, Sleijfer DT. Willemse PH, et al. Eur J Cancer. 1990 Mar;26(3):345-52. doi: 10.1016/0277-5379(90)90232-i. Eur J Cancer. 1990. PMID: 2141492

9

Modification of 5-fluorouracil activity by high-dose methotrexate or leucovorin in advanced colorectal carcinoma.

Sinnige HA, Sleijfer DT, de Vries EG, Willemse PH, Mulder NH. Sinnige HA, et al. Among authors: willemse ph. Eur J Cancer. 1990;26(5):625-8. doi: 10.1016/0277-5379(90)90094-a. Eur J Cancer. 1990. PMID: 2144754

10

Phase II study of carboplatin and cytosine arabinoside in patients with disseminated malignant melanoma.

Mulder NH, Sleijfer DT, de Vries EG, Schraffordt Koops H, Willemse PH. Mulder NH, et al. Among authors: willemse ph. J Cancer Res Clin Oncol. 1990;116(3):301-2. doi: 10.1007/BF01612907. J Cancer Res Clin Oncol. 1990. PMID: 2196265

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

246 results

Search Page

Filters